VWM
CORT icon

Vermillion Wealth Management’s Corcept Therapeutics CORT Stock Holding History

Vermillion Wealth Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6
Closed -$242 – 1732
2026
Q1 		$242 Buy
+6
New +$224 ﹤0.01% 1262

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vermillion Wealth Management's CORT Position: Q2 2026 in Review

Vermillion Wealth Management sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 6 shares — an estimated $242 sold.

Vermillion Wealth Management first reported a position in CORT in Q1 2026 and held it in 1 quarter. The position peaked at $242 in Q1 2026. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Vermillion Wealth Management reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vermillion Wealth Management sold 6 Corcept Therapeutics shares in Q2 2026, an estimated $242.
  • Vermillion Wealth Management first reported a position in Corcept Therapeutics in Q1 2026 and held it in 1 quarter.
  • Vermillion Wealth Management's Corcept Therapeutics position peaked at $242 in Q1 2026.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Vermillion Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.